or complications, time to start ambulation and time to start lactation.

RESULTS: The maternal characteristics at randomization between the groups were no different including: gestational age, blood pressure, laboratory parameters, and the use of antihypertensives. No maternal deaths occurred in either group. There were no differences in the rate of eclampsia or maternal complications such as hemorrhage, respiratory depression and severe hypertension between the groups. Time to ambulation and time to lactation were significantly shorter in the no Mag group. (Table)

CONCLUSION: In this large randomized study the use of Mag for 24 hours post partum in patients with severe preeclampsia that had received at least 8 gm of Mag prior to delivery, was not associated with a reduction in eclampsia or other maternal complications post partum.

	Mag N=555	No Mag N=558	p value
Eclampsia N(%)	1(0.18)	2(0.35)	0.99
Hemorrhage N(%)	11(2.0)	13(2.3)	0.76
Resp. Depression N(%)	5(0.9)	4(0.7)	0.67
Severe HTN N(%)	53(9.5)	50(9.0)	0.60
Time to amb. (hours)	18.1 ± 10.6	11.8 ± 10.8	0.0001
Time to lact. (hours)	24.1 ± 17.1	17.1 ± 16.8	0.0001

5 Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history (the eppi trial): an open-label international multicentre randomized controlled trial

Katie Groom[1], Lesley McCowan[1], Laura MacKay[1], Joanne Said[2], Stefan Kane[2], Susan Walker[2], Saskia Middeldorp[3], Peter Stone[1], Claire McLintock[4], The EPPI Trial Study Group

[1]University of Auckland, Auckland, New Zealand, [2]University of Melbourne, Melbourne, Australia, [3]University of Amsterdam, Amsterdam, Netherlands, [4]Auckland Dictrict Health Board, Auckland, New Zealand

OBJECTIVE: To determine whether daily enoxaparin commenced prior to 16+0 weeks' gestation, in addition to standard high risk care (SHRC), reduces the recurrence of pre-eclampsia and/or fetal growth restriction in women deemed to be at high risk of these conditions based on their past obstetric history.

STUDY DESIGN: An open-label randomised controlled trial in five obstetric units in New Zealand, Australia and the Netherlands. Inclusion criteria were: $\geq 6^{+0}$ and $\leq 15^{5+6}$ weeks' gestation with fetal viability and singleton pregnancy confirmed, and most recent pregnancy complicated by (i) pre-eclampsia delivered $\leq 35^{+6}$ weeks, (ii) small for gestational age (SGA) $<10^{th}$ customised birthweight centile (CBWC) delivered $\leq 35^{+6}$ weeks, or (iii) SGA$\leq 3^{rd}$ CBWC delivered at any gestation. Women were randomly assigned to SHRC plus enoxaparin 40mg subcutaneously daily or SHRC only. SHRC included prescription of daily low dose aspirin and calcium. Randomisation was stratified according to inherited thrombophilia status. Uterine and umbilical artery Doppler waveform studies were performed at 20 and 24 weeks' gestation and serum samples were taken for assessment of placental and angiogenic markers at recruitment, 20 and 30 weeks' gestation. The primary outcome was the incidence of pre-eclampsia and/or SGA $<5^{th}$ CBWC. Based on the available literature the sample size was calculated to assess a reduction in the primary outcome from 25% to 7% (160 women required with 5% drop-out rate provides 80% power at a 2-sided significance level 0.05). This was an intention to treat analysis. ACTRN12609000699268.

RESULTS: Data were analysed for 156 women, 8 women delivered <20 weeks and were not included in further analysis. Preeclampsia and/or SGA $<5^{th}$ CBWC occurred in 35 women (23.5%). Enoxaparin in addition to SHRC did not reduce the rate of preeclampsia and/or SGA $<5^{th}$ CBWC (OR 1.17, 95%CI 0.5-2.6) or of any secondary outcomes (table).

CONCLUSION: In women with a prior pregnancy complicated by preeclampsia and/or fetal growth restriction, the addition of enoxaparin to high risk obstetric care did not reduce the risk of recurrence.

Outcomes according to treatment group

Outcome	SHRC plus enoxaparin (n=71)	SHRC (n=77)	Odds ratio (95%CI) or p value
Pre-eclampsia and/or SGA <5th CBWC	18 (25%0	17 (22.1%)	1.17 (0.5-2.6)
Pre-eclampsia	6 (8.5%)	5 (6.5%)	1.28 (0.4-4.6)
SGA<5th CBWC	15 (20.8%)	13 (16.9%)	1.35 (0.6-3.2)
SGA<10th CBWC	23 (31.9%)	22 (28.6%)	1.16 (0.6-2.4)
Pre-eclampsia del <34+0 weeks	2 (2.8%)	1 (1.3%)	2.02 (0.1-28.4)
Stillbirth/neonatal death	1 (1.4%)	3 (3.9%)	0.45 (0.04-5.7)
Mean gestational age at delivery (weeks + days)	37+5	37+1	p=0.45
Delivery <37 weeks	15 (21.1%)	19 (25.0%)	p=0.70
Mean birthweight	2999g	2907g	p=0.50
Mean CBWC	32.0	31.3	p=0.87

6 Prevention of preterm birth with pessary in singletons (PoPPS): a randomized controlled trial

Lorraine Dugoff[1], Vincenzo Berghella[2], Awathif D. Mackeen[3], Laura Goetzl[4], Jack Ludmir[1]

[1]University of Pennsylvania, Philadelphia, PA, [2]Thomas Jefferson, Philadelphia, PA, [3]Geisinger Health System, Danville, PA, [4]Temple University School of Medicine, Philadelphia, PA

OBJECTIVE: To determine if pessary use prevents preterm birth (PTB) in singleton gestations with a short transvaginal ultrasound (TVU) cervical length (CL) and without a prior spontaneous PTB.

STUDY DESIGN: Multicenter randomized controlled trial of asymptomatic women with singleton gestations with a TVU CL $\leq$ 25 mm at 18^0 - 23^6 weeks and no prior spontaneous PTB. Subjects were randomized to receive the Bioteque cup pessary or no pessary. Pessaries were inserted by MFM staff centrally trained in proper placement. Randomization was stratified by study site and CL($\leq$ 20 mm or >20-25mm). Treatment with vaginal progesterone was recommended to all women with a TVU CL $\leq$ 20 mm. Primary outcome was PTB<37 weeks. Composite adverse neonatal outcome included necrotizing enterocolitis, intraventricular hemorrhage (grade 3 or 4), respiratory distress syndrome, bronchopulmonary dysplasia, retinopathy, sepsis and neonatal death. Analysis was by intention-to-treat. Our required total sample size was 242. The trial was stopped prematurely by the DSMB due to the start of a competing NICHD MFMU pessary trial.

RESULTS: A total of 17,388 women were screened with TVU CL; 446 (2.6%) had a TVU CL $\leq$ 25 mm. Of the 394 (88.3%) who met eligibility criteria, 122 (31.0%) consented to randomization. As of the time of submission, 111 women have delivered, 56 (92%) in the pessary and 55 (90%) in the no pessary groups. Demographic characteristics, mean gestational age (21 $\pm$ 1 week) and mean CL (16 $\pm$ 7 mm) at enrollment were similar in both groups. There were no significant differences between the pessary and no pessary groups in rates of PTB<37 weeks, PTB<34 weeks, PTB<28 weeks, gestational